Investigational Drug Information for BGJ398
✉ Email this page to a colleague
What is the development status for investigational drug BGJ398?
BGJ398 is an investigational drug.
There have been 22 clinical trials for BGJ398.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 27th 2019.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Helsinn Healthcare SA.
There are one hundred and twenty-two US patents protecting this investigational drug and one international patent.
Summary for BGJ398
| US Patents | 122 |
| International Patents | 1,338 |
| US Patent Applications | 552 |
| WIPO Patent Applications | 290 |
| Japanese Patent Applications | 121 |
| Clinical Trial Progress | Phase 2 (2019-12-27) |
| Vendors | 75 |
Recent Clinical Trials for BGJ398
| Title | Sponsor | Phase |
|---|---|---|
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations | Labcorp Drug Development, Inc. | Phase 1/Phase 2 |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations | Helsinn Healthcare SA | Phase 1/Phase 2 |
| Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | Breast Cancer Research Foundation | Phase 1 |
Clinical Trial Summary for BGJ398
Top disease conditions for BGJ398
Top clinical trial sponsors for BGJ398
US Patents for BGJ398
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BGJ398 | ⤷ Try a Trial | Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein | Astellas Pharma Inc. (Tokyo, JP) | ⤷ Try a Trial |
| BGJ398 | ⤷ Try a Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try a Trial |
| BGJ398 | ⤷ Try a Trial | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| BGJ398 | ⤷ Try a Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BGJ398
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BGJ398 | Australia | AU2013228389 | 2032-03-08 | ⤷ Try a Trial |
| BGJ398 | Brazil | BR112014021897 | 2032-03-08 | ⤷ Try a Trial |
| BGJ398 | Canada | CA2865388 | 2032-03-08 | ⤷ Try a Trial |
| BGJ398 | China | CN104379740 | 2032-03-08 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
